VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients

Future Oncol. 2017 Feb;13(5):409-414. doi: 10.2217/fon-2016-0299. Epub 2016 Oct 26.

Abstract

Aim: Since VEGF polymorphisms were associated with variable protein production, we analyzed herein their roles in outcome of epithelial ovarian cancer (EOC) patients.

Methods: Genotypes of 85 patients with primary EOC were identified in DNA by real-time PCR. Progression-free survival and overall survival were analyzed using Kaplan-Meier method, univariate Cox model and bootstrap resampling study.

Results: At 60 months of follow-up, progression-free survival was shorter in patients with VEGF c.-2578 CC genotype compared with others (52.7 vs 82.2%; p = 0.04). Those patients had 2.15 more chance of presenting disease progression than others (p = 0.04); bootstrap study validated the result (p = 0.03).

Conclusion: Our data suggest that VEGF c.-2578C>A polymorphism acts as a prognostic factor in EOC.

Keywords: VEGF; epithelial ovarian cancer; genetic polymorphism; prognosis.

MeSH terms

  • Alleles
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Ovarian Epithelial
  • Female
  • Follow-Up Studies
  • Genotype
  • Humans
  • Kaplan-Meier Estimate
  • Linkage Disequilibrium
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial / drug therapy
  • Neoplasms, Glandular and Epithelial / genetics*
  • Neoplasms, Glandular and Epithelial / mortality*
  • Neoplasms, Glandular and Epithelial / pathology
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / mortality*
  • Ovarian Neoplasms / pathology
  • Patient Outcome Assessment
  • Polymorphism, Single Nucleotide*
  • Prognosis
  • Vascular Endothelial Growth Factor A / genetics*

Substances

  • Vascular Endothelial Growth Factor A